2015 March 20

A new paper validates WPSS for Myelodysplastic Syndromes and provides relevant in formation for the implementation of risk-adapted strategies in MDS

Dr Francesc Solé, leader of the Myelodysplastic Syndrome group at the Josep Carreras Research Institute has taken part in an international study. The publication establishes a new international benchmark indicator to improve the prognostic stratification of patients suffering myelodysplastic syndromes (MDS). 

The international prognosis indicator IPSS-R (International Prognostic Scoring System) has been used for MD syndromes since 2012 (Greenberg et al., Blood 2012).  One flaw was that it did not take transfusional needs into account and they are an important indicator for predicting the development of the disease. Patients with an MDS diagnosis who require more transfusions have a worse prognosis, which can affect their survival or the risk of their disease becoming acute leukaemia.

The work was carried out internationally and gathered clinical information from patients over 16 years old suffering from de novo MDS in several countries. From the data, researchers, including Dr Solé’s team, have established a new prognostic classification called WPSS-R, (Della Porta M et al. Leukemia, 2015), which completes the previous one and improves MDS patient categorization depending on their cytogenetic alterations, the WHO diagnosis, transfusional needs and parameters such as blasts, cytopenia, haemoglobin, platelets and the patients age.

 "Validation of WHO classification-based prognostic Scoring System (WPSS) for myelodysplastic Syndrome and comparison with the revised International prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM)".